Notice of GM and Proposed Change of Name

AI SummaryClose X

N4 Pharma plc announced its intention to change its name to Thalia Therapeutics plc, subject to shareholder approval at a general meeting scheduled for March 17, 2026. This proposed name change reflects the company's strategic shift towards developing innovative RNA-based therapeutics, complementing its existing Nuvec® gene delivery system. The company's trading identifier will change to THAT, while its LEI, ISIN, and SEDOL will remain the same. Existing share certificates will continue to be valid.

Disclaimer*

UK 100

Latest directors dealings